Insight

The use of surrogate endpoints in solid and haematological cancers

Photo from Timothée Olivier/X

Oct 8, 2024, 13:20

The use of surrogate endpoints in solid and haematological cancers

Ash Paul, Medical Director at EoE Specialised Commissioning Group, UK, shared a post on X:

“Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more.”

Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more

Authors: Timothée Olivier, Alyson Haslam, Dagney Ochoa, Eduardo Fernandez and Vinay Prasad.

Source: Ash Paul/X

Alyson Haslam Ash Paul cancer cancer awareness cancer care Dagney Ochoa Eduardo Fernandez fight against cancer Global fight against cancer haematological cancers OncoDaily Oncology Timothée Olivier Vinay Prasad

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success